Welcome to our dedicated page for Sonnet Biotherapeutc Hldng SEC filings (Ticker: SONN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode immuno-oncology jargon buried in Sonnet BioTherapeutics Holdings Inc (SONN) disclosures? Each 10-K details FHAB platform breakthroughs, trial costs, and cash runway—yet stretches over 200 pages. Problem: extracting what really matters before the next data readout or capital raise takes hours.
Solution: Stock Titan’s AI lifts the fog around Sonnet BioTherapeutics SEC filings explained simply. Our engine delivers plain-English highlights the moment a document hits EDGAR, whether it’s a Sonnet BioTherapeutics quarterly earnings report 10-Q filing spelling out liquidity, or an Sonnet BioTherapeutics 8-K material events explained alerting you to new trial initiations. Need to monitor insider sentiment? Get instant pings on Sonnet BioTherapeutics Form 4 insider transactions real-time and drill into every Sonnet BioTherapeutics executive stock transactions Form 4—no more manual searches.
Our coverage spans every form: the Sonnet BioTherapeutics annual report 10-K simplified for R&D spend trends, Sonnet BioTherapeutics proxy statement executive compensation to see how milestones drive pay, plus S-1, 424B, and Section 16 filings. AI-powered summaries spotlight cash burn trajectories, FHAB patent updates, and pivotal trial endpoints, turning dense biotech language into actionable insights.
Whether you’re investigating Sonnet BioTherapeutics insider trading Form 4 transactions ahead of catalyst dates, running a Sonnet BioTherapeutics earnings report filing analysis, or simply understanding Sonnet BioTherapeutics SEC documents with AI, our real-time dashboard keeps you a step ahead—without wading through PDFs.
Sonnet BioTherapeutics Holdings, Inc. provides an annual update as a clinical-stage biotech focused on oncology and neuropathy, built around its proprietary FHAB albumin-binding platform to extend cytokine half-life and target tumors.
The lead program, SON-1010 (IL12-FHAB), has dosed 103 patients and healthy volunteers across three Phase 1 studies, showing prolonged interferon gamma responses, manageable safety with no dose-limiting toxicities, and early clinical benefit in advanced solid tumors and platinum-resistant ovarian cancer, including partial and complete responses at the highest doses and ongoing expansion cohorts.
SON-080, a low-dose IL-6 for chemotherapy-induced and diabetic peripheral neuropathy, showed tolerability and symptom-improvement signals in a small Phase 1b group and is now licensed to Alkem in India with a $1.0 million upfront payment plus potential milestones and low double-digit royalties, while SON-1210, a bifunctional IL-12/IL-15 construct, has completed IND-enabling toxicology and is planned for an investigator-initiated Phase 1/2a study in metastatic pancreatic cancer. The company highlights a history of operating losses and a need for significant additional capital, with aggregate non-affiliate common equity valued at $4,150,174 on March 31, 2025, based on a $1.34 share price.
Sonnet BioTherapeutics Holdings, Inc. filed a post-effective amendment to multiple Form S-3 registration statements to end all registered securities offerings following its merger into Hyperliquid Strategies Inc. On December 2, 2025, through a series of mergers, Sonnet became a direct wholly owned subsidiary of Hyperliquid Strategies, and Rorschach I LLC became its affiliate subsidiary.
The amendment terminates the effectiveness of the listed Form S-3 registration statements and removes from registration all securities that had been registered but remained unsold, including offerings such as up to 5,770,14 shares of common stock issuable upon exercise of outstanding warrants and a mixed shelf for up to $100 million of various securities. After this action, Sonnet no longer has securities registered for sale under these S-3 registration statements.
Sonnet BioTherapeutics Holdings, Inc. has filed a post-effective amendment to multiple Form S-3 registration statements to terminate their effectiveness and deregister all securities that had been registered but remain unsold. This action follows completion of a business combination on December 2, 2025, in which Sonnet became a direct wholly owned subsidiary of Hyperliquid Strategies Inc. through successive mergers involving Rorschach I LLC and two merger subsidiaries.
With this amendment, Sonnet confirms that all offerings under these S-3 registration statements, including a shelf that had allowed issuance of up to $100 million of various securities, have been terminated, and there are no remaining securities registered by Sonnet under these statements.
Sonnet BioTherapeutics Holdings, Inc. filed a post-effective amendment to its Form S-3 registration statements to deregister all securities that remain unsold under those registrations. The company has terminated all offerings of securities pursuant to these Form S-3 registration statements.
This step follows a business combination completed on December 2, 2025, in which Rorschach Merger Sub merged into Rorschach I LLC and, immediately afterward, Company Merger Sub merged into Sonnet, leaving Sonnet as a direct wholly owned subsidiary of Hyperliquid Strategies Inc. After this amendment, there will be no remaining securities registered by Sonnet under the affected Form S-3 registration statements.
Sonnet BioTherapeutics Holdings, Inc. filed a post-effective amendment to multiple Form S-1 registration statements. The move follows a December 2, 2025 business combination in which Sonnet became a direct wholly owned subsidiary of Hyperliquid Strategies Inc. In connection with that merger, Sonnet has terminated all offerings under these S-1s and, consistent with its prior undertakings, is removing from registration all securities that remained unsold. After giving effect to this amendment, there will be no securities left registered by Sonnet under the affected Form S-1 registration statements.
Sonnet BioTherapeutics Holdings, Inc. director Susan Dexter reported a change in her holdings tied to the company’s merger with Hyperliquid Strategies Inc. On December 2, 2025, 9,643 shares of Sonnet common stock were disposed of, leaving her with zero Sonnet shares held directly after the transaction.
The transaction occurred in connection with a Business Combination Agreement among Sonnet, Rorschach I LLC, Hyperliquid Strategies Inc., and related merger subsidiaries. In this deal, Rorschach became a wholly owned subsidiary of Hyperliquid Strategies Inc., and Sonnet was merged into a separate subsidiary and survived as a direct wholly owned subsidiary of Hyperliquid Strategies Inc.
The filing notes that 8,000 restricted stock units granted on July 11, 2025 and 1,643 previously vested restricted stock units were included in these holdings. At the effective time of the merger, each Sonnet restricted stock unit was exchanged for one-fifth of a share of Hyperliquid Strategies Inc. common stock and one contingent value right, with all amounts reflecting Sonnet’s prior reverse stock splits.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) has adjourned its special stockholder meeting to give investors more time to vote on the proposed business combination with Hyperliquid Strategies Inc. (HSI) and Rorschach I LLC. The company states that more than 95% of the shares already voted on the transaction have supported the deal, but approval still requires a majority of all outstanding shares.
The special meeting is rescheduled for 9:00 a.m. Eastern Time on December 2, 2025, via a virtual link, with the board unanimously recommending that stockholders vote in favor of all proposals. HSI’s shares have been approved for listing by Nasdaq upon completion of the transaction, while Sonnet highlights its oncology-focused FHAB platform as the core of its biologic drug development strategy.
Sonnet BioTherapeutics Holdings, Inc. reported that it has adjourned its special stockholder meeting to 9:00 a.m. Eastern Time on December 2, 2025. The meeting was postponed to give investors more time to vote on the proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC, along with other related proposals. Stockholders who were of record on October 20, 2025 remain entitled to vote and may attend the reconvened virtual meeting via the provided web address. The company also highlighted that additional details about the transaction are available in the previously mailed proxy statement/prospectus and other SEC filings.
FAQ
What is the current stock price of Sonnet Biotherapeutc Hldng (SONN)?
What is the market cap of Sonnet Biotherapeutc Hldng (SONN)?
